: It should not be used concurrently with MAO inhibitors or within 14 days of stopping them.
: Because opioids can cause significant constipation, bowel function should be routinely monitored. Patients are often encouraged to increase fluid and fiber intake or use stimulant laxatives if treatment exceeds 2–3 days. Contraindications and Risks
: Assess respiratory rate, pulse, and blood pressure before and during administration. If the respiratory rate drops below 10 per minute, the patient should be checked for sedation and respiratory depression. 110353
Topic is a reference number for the drug Chlorpheniramine Polistirex/Codeine Polistirex , better known by its trade name Tuxarin ER . This extended-release medication is primarily used for the relief of cough and upper respiratory symptoms associated with allergies or the common cold. Therapeutic and Pharmacologic Classification
For more specific information on dosing and detailed pharmacology, refer to professional resources like the Nursing Central Drug Guide or the Washington Manual . Chlorpheniramine Polistirex/codeine Polistirex (Tuxarin ER) : It should not be used concurrently with
: Crushing, chewing, or snorting the extended-release product can lead to an uncontrolled delivery of codeine, which may result in a fatal overdose.
: Acts directly on the cough center in the brain to suppress the cough reflex. Key Assessment & Safety Monitoring This extended-release medication is primarily used for the
: Allergy, cold, and cough remedy; antitussive.